trastuzumab biosimilar (Bionovis/Fiocruz/IVB)

N/A

Report date: 2025/03/20 09:37:49

Base Information

Drug Nametrastuzumab biosimilar (Bionovis/Fiocruz/IVB)
Drug Alias NameN/A
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanizedBiologics > Biosimilar
Mechanisms of ActionReceptor protein-tyrosine kinase erbB-2 antagonists
TargetsReceptor protein-tyrosine kinase erbB-2
Therapy Area/IndicationsMetastatic breast cancerStomach Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryBrazil
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesMerck Serono Sa
China Registration ClassN/A

Develop Information

Active CompaniesInstituto Vital BrazilFundacao Oswaldo CruzBionovis
Inactive CompaniesN/A
Active IndicationsMetastatic breast cancerStomach Neoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A